Véronique Cruciani

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers

Urs B. Hagemann, Christine Ellingsen, Joachim Schuhmacher et al. · Clinical Cancer Research · 2019 · 108 citations

Medicine, Oncology, Pharmacology +17

Evolutionary selection pressure and family relationships among connexin genes

Véronique Cruciani, Svein‐Ole Mikalsen · Biological Chemistry · 2007 · 63 citations

Life Sciences, Evolutionary Biology, Zoology +13

Ischemia Induces Closure of Gap Junctional Channels and Opening of Hemichannels in Heart-derived Cells and Tissue

David Johansen, Véronique Cruciani, Rune Sundset et al. · Cellular Physiology and Biochemistry · 2011 · 62 citations · Full text

Life Sciences, Cardiology, Cell Biology +15

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy

Pascale Lejeune, Véronique Cruciani, Axel Berg‐Larsen et al. · Journal for ImmunoTherapy of Cancer · 2021 · 52 citations · Full text

Life Sciences, Immunology, Oncology +17

Synergistic Effect of a Mesothelin-Targeted ²²⁷Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models

Katrine Wickstroem, Urs B. Hagemann, Véronique Cruciani et al. · Journal of Nuclear Medicine · 2019 · 51 citations · Full text

Medicine, Oncology, Pharmacology +17